國家衛生研究院 NHRI:Item 3990099045/11413
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 856719      Online Users : 847
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/11413


    Title: Effects of statin use in advanced chronic kidney disease patients
    Authors: Huang, TM;Wu, VC;Lin, YF;Wang, JJ;Shiao, CC;Chen, L;Chueh, SJ;Chueh, E;Yang, SY;Lai, TS;Lin, SL;Chu, TS;Wu, KD;National Taiwan University Hospital Study Group on Acute Renal Failure
    Contributors: Institute of Population Health Sciences
    Abstract: Although statin treatment is recommended for patients with chronic kidney disease (CKD) stages I(-)IV, its potential benefits have not been reported in advanced CKD patients. Non-diabetic patients with advanced CKD (pre-dialysis patients, estimated glomerular filtration rate <15 mL/min/1.73 m(2)) were enrolled from a National Health Insurance Research Database with a population of 23 million. Statin users and non-users were matched using propensity scoring and analyzed using Cox proportional hazards models, taking mortality as a competing risk with subsequent end-stage renal disease (ESRD) and statin doses as time-dependent variables. A total of 2551 statin users and 7653 matched statin non-users were identified from a total 14,452 patients with advanced CKD. Taking mortality as a competing risk, statin use did not increase the risk of new-onset diabetes mellitus (NODM) or decrease the risk of de novo major adverse cardiovascular events (MACE), but reduced all-cause mortality (hazard ratio (HR) = 0.59 [95% CI 0.42(-)0.84], p = 0.004) and sepsis-related mortality (HR = 0.53 [95% CI 0.32(-)0.87], p = 0.012). For advanced CKD patients, statin was neither associated with increased risks of developing NODM, nor with decreased risk of de novo MACE occurrence, but with a reduced risk of all-cause mortality, mainly septic deaths.
    Date: 2018-09-17
    Relation: Journal of Clinical Medicine. 2018 Sep 17;7(9):Article number 285.
    Link to: http://dx.doi.org/10.3390/jcm7090285
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2077-0383&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000445635800059
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85114272652
    Appears in Collections:[Li-Kwang Chen] Periodical Articles

    Files in This Item:

    File SizeFormat
    PUB30227675.pdf958KbAdobe PDF386View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback